Australian medicinal cannabis company Althea Group Holdings
(ASX:AGH) through its wholly-owned subsidiary Althea MMJ has moved forward with plans to increase the number of patients prescribed medical cannabis in the UK.
They are set to work with Drug Science’s pilot “Project TWENTY21” - the UK’s first national pilot for medical cannabis and will launch next month.
It aims to enrol 20,000 patients before the end of 2021. Althea has been selected from a limited number of medicinal cannabis companies to supply, on commercial terms, its range of products to the Pilot.
They'll be focused on patients in which alternative treatment has failed such as Chronic pain, PTSD, with a focus on the veteran community, anxiety, multiple sclerosis and Tourette’s syndrome.
Shares in Althea Group Holdings
(ASX:AGH) closed 9.24 per cent higher at $1.01 yesterday.
